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Abstract
Health impact assessments (HIAs) inform policy and decision making by providing information 
regarding future health concerns, and quantitative HIAs now are being used for local and urban-
scale projects. HIA results can be expressed using a variety of metrics that differ in meaningful 
ways, and guidance is lacking with respect to best practices for the development and use of HIA 
metrics. This study reviews HIA metrics pertaining to air quality management and presents 
evaluative criteria for their selection and use. These are illustrated in a case study where PM2.5 
concentrations are lowered from 10 to 8 µg/m3 in an urban area of 1.8 million people. Health 
impact functions are used to estimate the number of premature deaths, unscheduled 
hospitalizations and other morbidity outcomes. The most common metric in recent quantitative 
HIAs has been the number of cases of adverse outcomes avoided. Other metrics include time-
based measures, e.g., disability-adjusted life years (DALYs), monetized impacts, functional-unit 
based measures, e.g., benefits per ton of emissions reduced, and other economic indicators, e.g., 
cost-benefit ratios. These metrics are evaluated by considering their comprehensiveness, the 
spatial and temporal resolution of the analysis, how equity considerations are facilitated, and the 
analysis and presentation of uncertainty. In the case study, the greatest number of avoided cases 
occurs for low severity morbidity outcomes, e.g., asthma exacerbations (n=28,000) and minor-
restricted activity days (n=37,000); while DALYs and monetized impacts are driven by the 
severity, duration and value assigned to a relatively low number of premature deaths (n=190 to 
230 per year). The selection of appropriate metrics depends on the problem context and 
boundaries, the severity of impacts, and community values regarding health. The number of 
avoided cases provides an estimate of the number of people affected, and monetized impacts 
facilitate additional economic analyses useful to policy analysis. DALYs are commonly used as an 
aggregate measure of health impacts and can be used to compare impacts across studies. Benefits 
per ton metrics may be appropriate when changes in emissions rates can be estimated. To address 
community concerns and HIA objectives, a combination of metrics is suggested.
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1. Introduction
Air quality management requires the consideration of a complex array of technical, 
economic, legal and political factors. In the U.S., statutory obligations are placed on state 
and local governments to attain ambient concentrations and meet other standards set by the 
US Environmental Protection Agency (US EPA). Historically, compliance with standards 
has been achieved by emission reduction strategies that addressed a single pollutant at a 
time, and targeted local and culpable sources for emission reductions, at the same time 
incorporating effects of the broader emission reductions accomplished by national emission 
standards. As air quality standards continue to be strengthened and easily implemented 
controls become rarer, decision makers must consider a wider range of policy measures. 
Since interventions aimed at reducing ambient pollution levels can affect the health of those 
living and working in the affected area (Henschel et al., 2012), it is becoming increasingly 
important to assess the nature and magnitude of potential health impacts, thus avoiding both 
unintended health consequences and missed opportunities to improve public health (NRC, 
2011).
Health impact assessments (HIAs) use a variety of techniques to evaluate and compare 
potential health impacts of proposed projects, policies and plans with the key objectives of 
understanding the direction, magnitude, severity and distribution of impacts (Bhatia et al., 
2014). HIAs and similar analyses have been conducted at multiple scales and for different 
purposes. At the national or global scale, accountability research, burden of disease, and 
other studies are used to evaluate the disease burden due to pollution (Fann et al., 2012b; 
Lim et al., 2012), the incremental impact of alternative policies and scenarios, e.g., different 
levels of an ambient standards (Chanel et al., 2014; Dias et al., 2012; Heal et al., 2013), to 
apportion health impacts by source industry (Fann et al., 2013), and to explain the benefits 
of standards, e.g., the avoided 230,000 premature deaths annually by 2020 due to 
implementation of PM2.5 controls between 1990 and 2005 in the US (US EPA, 2011). At 
regional (sub-national), urban and project scales, HIAs can be conducted in a policy context, 
but more commonly to gauge potential impacts and benefits of specific actions. In particular, 
HIAs conducted by health departments, academic researchers or advocacy groups often aim 
to incorporate health outcomes in policy and decision making (Dannenberg and Wernham, 
2013).
Due to limitations in the scope and available data, most HIAs have been qualitative rather 
than quantitative (Rhodus et al., 2013). While qualitative assessments can convey the 
direction and magnitude of impacts, quantitative methods offer more explicit information 
regarding impacts of potential interventions or the status of abatement policies (Bhatia and 
Seto, 2011). Several guides for the design and implementation of HIAs have provided 
recommendations for screening, scoping, and impact assessment steps of the HIA process. 
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However, there are few recommendations for reporting and communicating results (Hebert 
et al., 2012). Metrics that effectively communicate impacts to stakeholders and decision-
makers need to be identified.
Tools developed to facilitate the systematic quantification of impacts produce different 
metrics. The Environmental Benefits Mapping and Analysis Program (BenMAP) developed 
by the US EPA and the Air Quality Benefits Assessment Tool (AQBAT) used by Health 
Canada report impacts as attributable cases and monetized impacts (Judek et al., 2006; US 
EPA, 2015a). Air pollution accountability research tends to favor these metrics (Bell et al., 
2011). The Integrated Environmental Health Impact Assessment System developed for the 
European Union (Briggs, 2008) uses time-based health metrics (e.g., disability adjusted life 
years, DALYs). Originally developed for the comparative risk assessment framework 
(Murray, 1994), these metrics summarize different health effects with varying degrees of 
severity into a single figure (de Hollander and Melse, 2006; Hofstetter and Hammitt, 2002).
Health impacts associated with air pollution vary by duration (chronic or transient), degree 
(severe or minor) and temporality (caused shortly after exposures or lagged by several 
years). Urban-scale HIAs can address projects or policies that affect the entire urban area or 
a specific segment of the population. Thus, the applicability of the certain health metrics 
may depend on the boundary of the HIA, the severity of the predicted impacts, and 
community values regarding health. Previous reviews have discussed differences between 
qualitative and quantitative HIAs (Bhatia and Seto, 2011; O’Connell and Hurley, 2009), but 
the types of metrics used in quantitative urban-scale HIAs have not been addressed.
The goal of this paper is to evaluate quantitative metrics used in HIAs and similar analyses 
that are relevant to air quality management at the urban and potentially regional scales. The 
metrics are evaluated using explicit criteria, and demonstrated using a case study that 
focuses on particulate matter less than 2.5 µm in diameter (PM2.5). The paper concludes 
with recommendations for those metrics that can best inform decision-makers.
2. Methods
Literature published between 2011 and 2015 was reviewed to identify HIA metrics used for 
both project and policy applications. Reviews and critiques of HIAs (in both the peer-
reviewed and grey literature) and original peer-reviewed articles were examined, and 
included studies that evaluated the burden of disease attributable to ambient air pollution, 
the health benefits of proposed ambient air quality standards, and policies to reduce 
pollutant levels (e.g., active transport). The HIAs identified in the literature ranged in scale 
from multi-national to urban. Recent regulatory impact analyses (RIAs) by US EPA were 
also reviewed (US EPA, 2015b, 2014, 2012a). Selected metrics include the predicted 
number of cases, time-based metrics, impacts per unit emissions, and monetized impacts.
Evaluative criteria were identified from two sources. First, findings of the reviewed 
quantitative HIAs were used to identify key characteristics relevant to air quality metrics, 
e.g., metrics should account for population dynamics since pollution-related health effects 
can lag years behind exposures (Flachs et al., 2013). Second, review articles and 
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commentaries from the health indicator literature were examined to identify additional 
criteria, e.g., the comparability of metrics across populations of different size (Walker et al., 
2007).
A case study demonstrates the formulation, use, strengths and limitations of the metrics. 
This uses Detroit, Michigan and the surrounding county (Wayne), a mostly urban and 
suburban region (area of 1600 km2, population of 1.8 million) that has a mix of industrial, 
commercial, area and mobile emission sources. The county scale was selected due to the 
availability of emission and other data. A scenario is evaluated in which PM2.5 
concentrations are uniformly lowered across the county from 10 to 8 µg/m3, reflecting a 
policy that reduces concentrations below the current national annual average standard of 12 
µg/m3 (US EPA, 2013a). The analysis follows the method reported by Fann et al. (2012) 
with several differences. To examine potential differences between HIA methodologies, two 
methods (detailed below) are used to estimate mortalities attributable to changes in PM2.5 
levels. In addition to the concentration-response (CR) estimates included in the BenMAP 
software, cause-specific mortality CR estimates developed for the recent Global Burden of 
Disease (GBD) study (Burnett et al., 2014; Lim et al., 2012) are used. To assess the 
sensitivity of results to national, county and local scale data, attributable rates for premature 
mortality are calculated using baseline rates for the US as a whole, Wayne County 
(including Detroit), and Detroit separately. To facilitate these analyses, a simple spreadsheet 
model is used that does not represent spatial differences in air quality, population or impacts 
across the study area. Uncertainty in the number of avoided cases predicted for the case 
study is simulated using a Monte Carlo (MC) analysis (@Risk for Excel, Palisade 
Corporation). For each CR estimate, the distribution around the regression coefficient is 
specified based on the reported standard error. The simulation uses 5000 iterations to 
estimate the mean number of avoided cases and to construct 95% confidence intervals 
around the mean. The uncertainty in the number of avoided cases is propagated to the 
DALY and monetized impact metrics. Other sources of uncertainty for these summary 
metrics, e.g., uncertainty in disability weights or monetized values, are not included.
Additional information on the case study is found in the supplemental materials.
Emissions-based metrics (e.g., benefits per ton) use sector-specific 2011 PM25 emissions 
information for Wayne County (US EPA, 2012b). Annual emission rates are listed in 
Supplemental Table S6. Following source apportionments performed for Detroit (Buzcu-
Guven et al., 2007; Gildemeister et al., 2007), half (5 µg/m3) of the initial and existing 
PM2.5 is assumed to arise from local sources (e.g., direct PM25 emissions from industrial 
point sources, diesel and gasoline mobile sources, construction and road dust emissions, 
other non-point sources) that collectively emit approximately 7,000 tons per year; the other 
half arises from regional sources and the formation of secondary PM2.5. Using a “roll-back” 
method, a 2 µg/m3 reduction is achieved by reducing local emissions by 40%, or 2,800 tons 
per year. While simple, this approach attains results that reflect those from more complex 
methods that explicitly model sources and spatial variation (described later), and that are 
suitable for demonstrating the alternative health metrics. The benefits per ton metric is 
calculated by dividing avoided impacts (e.g., avoided cases and monetized impacts per year) 
estimated using a health impact function by the emission reduction.
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3.1 HIA metrics in previous air quality and other studies
HIA applications have been summarized and critiqued in several reviews published in the 
peer-reviewed and 'grey' literature (Bhatia and Seto, 2011; Dannenberg and Wernham, 2013; 
Hebert et al., 2012; O’Connell and Hurley, 2009; Rhodus et al., 2013; Schuchter et al., 
2014). Many HIAs have been made publically available (Pew Charitable Trusts, 2014; 
UCLA HIA-CLIC, 2015). The following emphasizes HIAs involving air quality analyses.
Most urban scale HIAs have been conducted for urban planning, transportation and land use 
projects. In a review of 81 transportation, housing and infrastructure, land use and waste 
management HIAs conducted between 1999 and 2012 in the United States, 52% considered 
air quality impacts, in part due to the availability of models and other assessment tools, but 
only 28% used quantitative methods (Rhodus et al., 2013). In contrast, nearly all (37 out of 
38) HIAs examined in the peer-reviewed literature used quantitative metrics, and most of 
these studies (71%) were conducted outside of the United States. (These studies are 
summarized in Supplemental Table S1.) Typically, impacts are reported as the number of 
(avoided) cases attributable to changes in ambient concentration. Fewer studies have 
reported impacts using DALYs or monetized impacts. Only eight of these HIAs used 
multiple metrics. Sometimes these metrics were calculated using standardized platforms, 
e.g., BenMAP. Other metrics in HIAs or regulatory analyses include cost-effectiveness and 
cost-benefit indicators. A few studies used indicators designed for life cycle assessment 
(LCA). These metrics are detailed below.
3.1.1 Predicted cases—As noted, the most common quantitative HIA metric is the 
number of morbidities or premature mortalities attributed to a change in pollutant 
concentration. The number of predicted cases is calculated using two similar approaches. 
The population attributable fraction (PAF) method, endorsed by the WHO (Prüss-Ustün et 
al., 2003), represents the fraction of risk for an outcome attributable to a specific exposure. It 
is estimated for specific exposure concentrations using concentration-dependent relative 
risks (RR):
(1)
where RR = relative risk for the outcome, e.g., eβΔx for a log-linear risk coefficient where Δx 
= change in ambient concentration, β = the regression coefficient, and Pe = the probability of 
exposure (i.e., the fraction of the population that is exposed; Steenland and Armstrong, 
2006). For air pollution, the PAF is typically used to estimate the burden of disease relative 
to non-anthropogenic background levels. Multiplying the PAF by the baseline rate in the 
population (y0, cases person-1 year-1) and the number of people in the population (P) gives 
the number of attributable cases in the population. Recently, this approach has been used to 
estimate the burden of disease attributable to air pollution (Cárdaba Arranz et al., 2014; 
Hänninen et al., 2014), and to compare PM2.5 standards in Taiwan (Yang and Kao, 2013).
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The second method uses a health impact function (HIF) to estimate changes in outcome 
incidence. The HIF represents a simplified PAF where the entire population is considered 
exposed (e.g., Pe=1). The HIF depends on the form of the CR function, e.g., a log-linear CR 
estimate gives:
(2)
where ΔY = incremental change in the number of cases, y0 = baseline incidence rate (cases 
person-1 year-1), β = CR estimate (log relative risk), Δx = expected or measured change in 
concentration (µg/m3 or ppb), and P = exposed population (US EPA, 2015a). The HIF can 
estimate the incidence attributable to pollution relative to 'pristine' or 'background' levels 
(Fann et al., 2012b), but generally is used to evaluate incremental impacts associated with a 
change in concentration, e.g., effects of a new standard relative to existing concentrations 
(Berman et al., 2012; Boldo et al., 2014; US EPA, 2012a).
Both PAF and HIF methods require information including the size of the exposed 
population, baseline incidence rates for diseases associated with pollutants, baseline and 
exposure concentrations, and CR estimates or relative risks for each pollutant-outcome pair. 
Prospective applications also require projections of population size and baseline rates; 
retrospective applications need current and historical data. CR estimates are drawn from the 
epidemiological literature, including large observational studies (e.g., Jerrett et al., 2009; 
Krewski et al., 2009), as well as smaller studies of targeted populations (e.g., Mar et al., 
2004). CR estimates can be chosen from a single study or pooled across multiple studies. 
'Counterfactual' concentrations (CFCs) for PM2.5 between 5.8 and 8.8 µg/m3 have been used 
as comparison or baseline conditions to represent non-anthropogenic 'background' levels 
(Burnett et al., 2014; Krewski et al., 2009; Murray et al., 2003).
3.1.2 Disability-adjusted life years—Duration metrics consider the time lived with 
disability or the time lost due to early death, and are derived from the number of predicted 
cases. Years of life lost (YLL) is the difference between the age-specific remaining life 
expectancy (LE) and the age of premature death. Years living with a disability (YLD) is the 
time spent living with a morbidity (i.e., the case duration), weighted by a disability weight 
(DW) that reflects the degree of impairment as assigned using trade-off methods (Prüss-
Ustün et al., 2003), e.g., panel evaluation judging which hypothetical person with a 
randomly assigned disease is healthier (Salomon et al., 2012). YLL and YLD are calculated 
for each population stratum (e.g., age group, sex, race/ethnicity):
(3)
(4)
where Nj,a = number of avoided cases in stratum j and age group a, LEa = standard 
remaining life expectancy for age group a (in years), D = duration of the disease state (in 
years), and DW = disability weight for the morbidity outcome. DWs range from 0 (perfect 
health) to 1 (death).
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The calculation of YLLs requires the use of standard life tables to determine the remaining 
life expectancy for each age group. Life tables can be developed for each year of life and 
particular age intervals using age-specific mortality rates for the population of interest 
(Anderson, 1999); this information is available at country and state levels (MDCH, 2015; 
World Health Organization, 2015).
DALY metrics sum YLL and YLD (eqs. 3 and 4) across the population, thus aggregating 
across different outcomes (e.g., asthma exacerbation and premature mortality). DALYs are 
commonly used in burden of disease studies (Flachs et al., 2013; Hänninen et al., 2014), and 
have been used in policy evaluations (Rojas-Rueda et al., 2013) and life cycle impact 
assessments (Kassomenos et al., 2013).
Quality-adjusted life years (QALYs) provide an alternative approach to DALYs. QALYs 
were developed to provide a comprehensive measure of health in multiple dimensions, e.g., 
physical health and social well-being (Gold et al., 2002) using weights that range from 1 
(perfect health) to 0 (death; Sassi, 2006). Weights assigned to QALYs are not tied to a 
particular disease status, but rather look at an individual’s overall health state. In contrast, 
DALYs use disability weights that focus on a single disease and comorbidities are not 
considered (Gold et al., 2002). In this paper, we used DALYs as a summary measure of 
health given their use in previous studies (Supplemental Table S1).
3.1.3 Monetized impacts—Mortality and morbidity outcomes can be monetized to 
facilitate cost-benefit and cost-effectiveness analyses. For deaths, valuations often use the 
value of a statistical life (VSL), a monetary value assigned to a premature mortality based on 
willingness to pay (WTP), derived as what an individual would pay to reduce their risk of 
dying in the next year by a small amount, e.g., 1 in 100,000 (Hammitt, 2000). An alternative 
measure is the value of a statistical life year (VSLY), a value assigned to each YLL rather 
than to each premature death (Hammitt, 2007). For morbidity, valuations use the WTP or the 
average cost of an illness (COI), which incorporates medical expenses and societal costs, 
e.g., lost wages (Akobundu et al., 2006). Valuations can be discounted to account for the 
time-value of money, e.g., for an assumed 20 year lag between a concentration reduction 
and premature mortality, US EPA (US EPA, 2012a), suggests apportioning 30% of the 
mortality in the year following the concentration reduction, 50% in the 2nd through 4th years, 
and the remaining 20% between 6th and 20th years, and applying discount rates from 3 to 
7% per year (OMB, 2003). Valuations without lags represent the “maximum impact” case 
since all impacts are assumed to occur immediately following the concentration change.
3.1.4 Functional unit-based metrics—Additional health metrics are used in life cycle 
assessments (LCA), which provide a comprehensive assessment of a product or service. 
Most LCAs use streamlined approaches that quantify impacts on the basis of a functional 
unit, e.g., per ton of PM2.5 emitted. Characterization factors relate environmental stressors 
evaluated in an LCA to health outcomes, e.g., the ReCiPe framework defines DALYs per kg 
of PM2.5 emitted (Goedkoop et al., 2009).
Regulatory analyses have used metrics expressed as outcomes per ton of emissions. Such 
metrics may be advantageous when changes in emissions (rather than ambient 
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concentrations) are estimated, e.g., a rule requiring increased efficiencies for residential 
wood-burning heaters estimated monetized benefits of $380,000 per ton of PM2.5 emissions 
reduced (US EPA, 2015). This metric was derived using the expected change in emissions, 
dispersion modeling to estimate concentrations, HIFs to predict avoided cases, and 
economic valuations to monetize outcomes (US EPA, 2013).
3.1.5 Economic metrics—Economic metrics incorporate health measures along with 
resource constraints, typically expressed as the cost of implementing a policy or project. For 
example, cost-effectiveness metrics using benefit-cost ratios can compare monetized 
benefits, in part derived from HIAs, to expected costs (Johannesson, 1995). Such metrics are 
sometimes required, e.g., proposed regulation in the US undergo a regulatory impact 
analysis to demonstrate their cost-effectiveness (US EPA, 2010). The total cost of an air 
quality management strategy includes the direct expenditures made by polluters, e.g., costs 
of equipment, operation and maintenance, subsidies and financial incentives, and costs to air 
pollution control districts for planning, monitoring and enforcement; benefits include all 
avoided health, social and environmental impacts (Bower and Brady, 1981). It can be 
difficult to monetize all benefits of air quality management, particularly for secondary and 
tertiary impacts, e.g., climate change mitigation; the scope and uncertainty of such analyses 
can present challenges. In addition, cost-benefit analyses may mask equity concerns given 
their focus on efficiency and overall costs and benefits, rather than benefits to specific 
groups (de Groot, 1998). Despite their complexity and limitations, cost-benefit analyses can 
help select effective strategies, particularly for multi-pollutant strategies that may have high 
implementation costs but substantial health benefits (Chestnut et al., 2006).
The present analysis focuses on health metrics. The PM2.5 reduction in the case study might 
be achieved by a number of management strategies, which would likely vary in costs. Given 
the study's emphasis, we did not identify a specific strategy and thus did not estimate control 
costs or calculate economic metrics. While a full discussion of economic metrics utilizing 
HIAs is beyond our scope, guidelines for conducting economic analysis for environmental 
policy assessment have been presented elsewhere (US EPA, 2010).
3.2 Case study
The case study uses a 2 µg/m3 reduction in PM2.5 concentrations to illustrate the health 
impacts of the health metrics in urban scale air quality HIAs. The metrics could be used to 
compare control strategies directly, and they might be incorporated into broader 
environmental impact assessments, such as those specified by the National Environmental 
Policy Act (Bhatia and Wernham, 2008). As discussed previously, they also are necessary 
for cost-benefit and cost-effectiveness analyses, although the present paper is limited to an 
analysis of health impacts. The next section discusses implications for using health metrics 
in air quality management.
3.2.1 Predicted impacts—HIA results for the case study are summarized in Table 1. 
Additional details are provided in Supplemental Tables S7 and S8. Lowering PM2.5 levels 
from 10 to 8 µg/m3 is estimated to prevent 190 premature all-cause deaths, 230 cause-
specific deaths (the sum of chronic obstructive pulmonary disease (COPD), lung, trachea 
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and bronchus cancers, ischemic heart disease (IHD), and stroke deaths), 28,000 avoided 
asthma exacerbations and 37,000 minor restricted activity days per year (MRAD), i.e., days 
when individuals avoid typical activities and instead switch to less strenuous tasks without 
missing work or school. Attributable rates for avoided premature deaths are higher when 
based on Detroit mortality rates compared to those for all of Wayne County or the U.S. 
(Table 2). Similar distributions of impacts have been reported in the several studies that 
evaluated both mortality and morbidity outcomes (Berman et al., 2012; Chart-asa and 
Gibson, 2015; Fann et al., 2013, 2012b; Jakubiak-Lasocka et al., 2015; Voorhees et al., 
2014). All of these studies show that less severe outcomes make up the majority of avoided 
cases.
Avoided YLL, YLD and DALYs in the case study total 3052, 47 and 3099 years, 
respectively (Table 3). YLL is largest for the 60–64 year age group (17 premature deaths 
contribute 394 YLL; Figure 1). Premature deaths account for 98.5% of the total DALYs 
avoided in the population. Among morbidity outcomes, asthma exacerbations make the 
greatest contribution to population DALYs (30 YLD per year, Supplemental Table S7). 
Comparable contributions of YLLs and YLDs to the overall DALY have been reported 
elsewhere (de Hollander et al., 1999; de Hollander and Melse, 2006; Hofstetter and 
Hammitt, 2002).
The total monetized health benefit of the 2 µg/m3 change in Wayne County exceeds $1.9 
billion annually, most of which (95%) is due to premature mortality (Table 3, Supplemental 
Table S7). The most important morbidity outcomes are non-fatal myocardial infarctions 
(n=160, $23 million) and unscheduled hospitalizations (n= 150, $5.5 million). More 
common but less severe outcomes include work loss days (n=21,000, $3 million) and 
MRADs (n=37,000, $2.5 million). Though less frequent, hospitalization outcomes account 
for a large share of the monetized morbidity impacts. The large and dominant contribution 
of mortalities to the total monetized value parallels the PM2.5 RIA (US EPA, 2012) and a 
recent HIA in China (Voorhees et al., 2014).
For emissions-based metrics, the total monetized benefit (all mortality and morbidity 
outcomes) is $660,000 per ton of PM2.5, again, mostly due to mortality ($640,000 per ton; 
Table 4). Expressed using the number of cases, the more severe outcomes had the lowest 
benefit per ton, e.g., premature mortality were only 0.07 deaths avoided per ton, while 
avoided asthma exacerbations were 9.8 cases per ton and avoided MRAD were 13.1 cases 
per ton. The literature shows a wide range but generally lower benefits ($46,000 to $510,000 
per ton PM2.5; Fann et al., 2012a). The higher estimates in the case study likely result from 
the simplified roll-back approach, which incompletely accounts for distance and dispersion 
between sources and people, e.g., reductions from elevated stacks and sources farther 
removed from populations are expected to have lower impacts per ton of pollutant emitted 
(Fann et al., 2009). Nevertheless, the estimates produced by the case study are reasonable 
given its limitations, e.g., uniform reduction and rollback approach.
3.2.2 Case study limitations—The case study has a number of limitations. First, the 
same age-stratified baseline rates were applied across the population, and other sources of 
variability (e.g., neighborhood, gender) were omitted. Second, the population was held 
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constant. Recent work demonstrates some sensitivity to population growth or mobility 
(Baccini et al., 2015; Flachs et al., 2013; Tchepel and Dias, 2011). Third, a single CR 
estimate was used, although other valid CR estimates are available and can be used to 
represent uncertainties (described later). Fourth, lags and discounting were ignored, which 
can overestimate premature mortality impacts and further increase the dominance of 
mortality impacts since YLL estimates are higher for deaths at younger ages (based on life 
expectancy). Fifth, the exposure scenario did not account for urban scale spatial 
heterogeneity (Batterman et al., 2014; Sparks et al., 2014), which should be considered to 
accurately predict impacts (Punger and West, 2013; Thompson et al., 2014). Sixth, impacts 
due to only PM2.5 were considered. Pollution control policies can affect multiple pollutants 
and have additional impacts and co-benefits. Lastly, both annual and daily concentrations 
were assumed to undergo the same change (2 µg/m3), following methods used in other HIAs 
(Fann et al., 2012b). However, this approach may underestimates changes in daily peak 
concentrations, which often arise from local sources, and it assumes that the same areas and 
populations are affected by annual and peak concentrations. Alternately, daily changes in 
PM2.5 and HIFs drawn from studies of short-term exposures could be used to determine 
short-term health impacts. Despite these limitations, the case study results mirror trends seen 
in other air pollution HIAs, and the evaluations and comparisons of the different metrics 
should be valid and applicable to other cities and scenarios.
3.3 Evaluation of HIA metrics
The criteria suggested for evaluating HIA metrics (Table 5) reflect several goals. First, 
metrics should be accurate and comprehensive with respect to the overall impacts expected 
on a population, otherwise impacts may be underestimated and lead to biased evaluations. 
Second, metrics should consider the spatial and temporal distribution of impacts, thus 
accounting for the variation in exposure and population susceptibility. This variation, along 
with equity considerations, will likely require stratification by factors related to individual or 
group-level susceptibilities, e.g., age, socioeconomic status, or race/ethnicity (O’Neill et al., 
2008). Third, since impacts are associated with both short- and long-term exposure to 
pollutants, and long-term impacts may lag several years, accounting for lags is important. 
Fourth, metrics should be easily understood by a wide audience, particularly given limited 
understanding of HIA techniques, pollutant impacts, and the presence of competing 
interests, e.g., economic or political considerations. Fifth, predicted impacts and valuations 
in the metrics are inherently uncertain, and uncertainties are propagated as the number of 
required data inputs increases. Both quantitative uncertainty analyses and descriptive 
characterizations are needed to describe uncertainties and aid interpretation. The next 
section contrasts each metric against the evaluative criteria, drawing on case study results to 
highlight key points. Table 6 summarizes this evaluation.
3.3.1 Predicted cases—The inclusion of MRAD, work loss days, and other transient but 
relatively common morbidity outcomes yields more comprehensive analyses by indicating 
the numbers of people potentially affected. This can increase the HIA's salience, especially 
for diseases like childhood asthma that represent important public health issues. The case 
study (like most other HIAs) included only those outcomes where the weight of evidence for 
an association is strong. Less evidence exists regarding associations between PM2.5 and 
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other outcomes, including cancer and adverse birth outcomes. Following US EPA methods 
(US EPA, 2012a), these impacts were excluded. Such omissions may lead to systematic 
negative biases (O’Connell and Hurley, 2009).
The CR function is arguably the most important and most uncertain input in predicting 
attributable cases. The case study used a single CR function for most outcomes. Other CR 
estimates may be valid and available, and can be used to bound expected ranges or show 
uncertainties, e.g., Fann et al. (2012) noted a 2.5-fold variation in the number of premature 
deaths using CRs derived from two large multicity observational studies (Laden et al., 2006; 
RR= 1.16 per 10 µg/m3 vs. Krewski et al., 2009, RR=1.06 per 10 µg/m3). This variation may 
reflect differences in study population demographics, exposure patterns, and other factors. 
CR estimates should be drawn from well conducted epidemiological studies with sufficient 
statistical power. For local-scale HIAs, city-specific CR estimates, ideally from large multi-
city studies, may be advantageous because they account for specific population 
characteristics. However, such estimates often are not available. Large multicity cohort 
studies or meta-analyses can have considerable statistical power, but may not be fully 
representative of the population for the HIA. When selecting CR estimates for local-scale 
HIAs, it is important to consider how the original study population differs from the one 
included in the HIA (Hubbell et al., 2009).
Table 2 demonstrates the sensitivity of HIA results to the baseline health data. Compared to 
national averages (CDC, 2014), attributable rates increase when using data specific to 
Wayne County (by 18%) and Detroit (by 22%). Thus, the same 2 µg/m3 reduction yields a 
larger impact in Detroit given the susceptible population. Using local data in urban-scale 
HIAs can account for population susceptibility. In addition, baseline health as well as other 
vulnerability or susceptibility factors are likely to be unevenly distributed across an urban 
region, e.g., rates of asthma hospitalizations vary 3-fold across the study region and some of 
the highest rates are seen in more polluted areas. Areas with higher asthma rates are 
expected to have more avoided asthma exacerbations than areas with lower rates, given the 
same PM2.5 level. The use of spatially-resolved health and exposure data should increase the 
accuracy of HIA results, and could allow for the development of strategies that target 
pollutant reductions in areas that confer the greatest benefits
Most (74%) of the cause-specific deaths are due to ischemic heart disease (IHD, 
Supplemental Table S8). The number of cause-specific deaths avoided (n=230) slightly 
exceeds the number of all-cause premature deaths (n=190; Table 1). The CR functions used 
for cause-specific mortality were developed specifically for the latest GBD study (Lim et al., 
2012). These non-linear functions were derived from studies examining ambient air 
pollution, active smoking, secondhand smoke exposure, and cooking smoke exposure 
(Burnett et al., 2014). The shape of each cause-specific CR curve differs (see Burnett et al., 
2014, Figure 1), e.g. for IHD, the slope is steeper at lower concentrations and tends to flatten 
at higher PM2.5 levels. At low concentrations (including the 8 to 10 µg/m3 in the present 
analysis) where the IHD CR function is steepest, the PAF method gives a higher number of 
cause-specific deaths than the all-cause deaths estimated by the HIF. Generally, predictions 
using non-linear CR functions depend on the baseline and scenario concentrations, e.g., 
lowering PM2.5 concentrations from 11 to 9 µg/m3 avoids 182 cause-specific mortalities 
Martenies et al. Page 11













(21% fewer deaths than the 10 to 8 µg/m3 scenario). The numbers of deaths predicted for 
these concentrations (679 and 498 deaths at 11 and 9 µg/m3, respectively) exceed those in 
the original case study (596 and 370 deaths at 10 and 8 µg/m3, respectively), but differences 
between the baseline and scenario deaths decreases at higher concentrations. These 
differences are small compared to uncertainties, as discussed below.
The case study also compared estimates of all-cause mortality predicted by the HIF and PAF 
methods using the same CR function from Krewski et al. (2009) (Table 1). For the specified 
scenario, the two methods gave the same number of avoided deaths (n=190). Differences 
between the HIF and PAF methods also result from differences in how health impacts are 
calculated, i.e., the HIF method uses the concentration difference (Δx = 2 µg/m3 in the 
scenario), while the PAF method compares attributable burdens across scenarios (Δx = 10 
µg/m3 – CFC). Thus, lowering PM2.5 from 20 to 18 µg/m3 still gives 190 avoided all-cause 
premature deaths using the HIF method, but PAF predictions decrease to 176 premature 
deaths. While these differences are small, the influence on DALYs and monetized impacts is 
large given the high values assigned to premature mortalities (discussed later).
The HIF (eq. 1) in the case study can predict short-term impacts, but with greater uncertainty 
than for long-term impacts. This paper focused on changes in long-term (annual average) 
concentrations, and mortality CR functions based on studies of chronic exposures were used, 
although the morbidity CR estimates came from short-term exposure studies (Supplemental 
Table S3). To derive short term impacts, it may be preferable to use mortality CR estimates 
drawn from short-term exposures studies (e.g., time series studies) with estimates of short-
term pollutant concentrations (e.g., daily PM2.5 concentrations). As noted earlier, short-term 
exposures likely will exhibit greater spatial and temporal variation than annual average 
concentrations, depending on proximity to the local emissions sources, meteorology, and 
other factors.
3.3.2 Disability-adjusted life years—YLLs, YLDs and DALYs facilitate comparison of 
impacts among different groups or cohorts in the population. For example, the number of 
avoided deaths in the 60–64 year age group is 36% lower than avoided deaths in the 80–84 
year age group, but the avoided YLLs in the younger group is 62% higher (Figure 1). Given 
the severity of premature deaths (quantified as the YLL), the 60–64 year age group receives 
the greatest benefit from the PM2.5 reduction. YLL may be particularly meaningful for 
premature mortality since deaths are delayed, rather than avoided (Rabl, 2003).
YLDs tend to deemphasize morbidity outcomes given the short durations of these impacts 
(e.g., 1 to 5 days) and the small DWs assigned (Table 3, Supplemental Table S4). For 
example, given the duration of an asthma exacerbation (0.005 years) and its DW (0.22), the 
28,000 asthma exacerbations avoided annually in the case study contributed only 30 YLDs 
to the total 3,100 DALYs predicted (Supplemental Table S7). For asthma, estimated YLDs 
due to emergency department visits or exacerbations may be underestimated since asthma 
exacerbations are under-reported (Reddel et al., 2009) and the time lost to avoidance 
behaviors (e.g., not participating in recreational activities) are excluded, potentially biasing 
HIA results.
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This discussion highlights several issues when disparate health outcomes are combined on 
the basis of duration and severity. In contrast, metrics using the number of cases avoided 
treat each outcome equally and avoid issues related to subjective weightings (de Hollander 
and Melse, 2006). Others argue that consideration of duration and severity is required to 
make trade-off comparisons between high and low impact outcomes (Wong et al., 2003).
3.3.3 Monetized Impacts—Like DALYs, monetized benefits of air pollution depend on 
outcomes included, but are driven by mortality, again due to the high value assigned to a 
statistical life. The VSL used for mortality ($9.6 million) far exceeds values for each 
morbidity outcomes (Supplemental Table S5). The lack of cessation lags and discounting in 
the case study is not expected to substantially alter results given the low social discount rates 
(3 to 7%) recommended (US EPA, 2012a). The valuation method endorsed by US EPA and 
used in the case study does not monetize deaths based on age using the VSLY or other 
approaches (unlike the DALYs in the previous section that considered the timing of death in 
estimating YLLs) (US EPA, 2010). VSL may overstate the value of premature deaths since 
deaths are delayed, rather than completely avoided. However, VSLY or methods that adjust 
VSL based on age can raise contentious issues regarding the value of a life saved for older 
populations (Robinson, 2007), and US EPA found little evidence to support age adjustments 
in VSL estimates (US EPA, 2010).
Monetized impacts, like DALYs, deemphasize morbidity outcomes due to their low and 
uncertain valuations. Morbidity outcomes are difficult to monetize accurately, and the WTP 
may underestimate the true societal costs. For example, asthma exacerbations accounted for 
only 0.08% of the total monetized impacts in the case study, despite being the second-most 
frequently avoided morbidity outcome (Supplemental Table S7). The value of $58 assigned 
to each exacerbation (Rowe and Chestnut, 1986) may incompletely account for medical 
costs or time lost at work or school. Monetized metrics may not reflect the sentiments of 
affected communities in Detroit and other urban areas where asthma outcome rates greatly 
exceed state and national norms (Wasilevich et al., 2008). The dominance of mortality 
outcomes has been demonstrated in Shanghai, China where air pollution-related deaths 
made up 92.5% of total monetized impacts (800 deaths monetized at 1.2 billion yuan 
compared to 420,000 morbidities monetized at 0.09 billion yuan) (Voorhees et al., 2014). 
Similarly, US EPA's recent RIA for ozone (O3) showed that 98% of the total monetized 
benefits ($2.0 to $3.4 billion) of a 70 ppb ozone standard would be due to avoided premature 
mortality from both short- and long term exposures (880 to 1,020 avoided deaths) (US EPA, 
2014).
Monetized metrics have been used in HIAs to facilitate comparisons among heath- and non-
health outcomes. For example, greater utilization of public transport that lowers pollutant 
levels (due to less personal vehicle use) will increase physical activity (due to additional 
walking), which promotes health. In a recent assessment of a Boston area proposal to alter 
transit pricing, the monetized impacts of physical activity ($75 million) far exceeded air 
pollution’s impacts ($1.5 million) (James et al., 2014). Including the co-benefits of air 
quality management can provide decision makers with information about the total impact of 
a strategy on public health, and potentially additional impetus for recommendations. Such 
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analyses can increase the HIA’s scope, complexity and uncertainty, but may be of particular 
value when the co-benefits are substantial.
3.3.4 Emissions based metrics—Emissions-based metrics are useful when it is more 
feasible to estimate changes in emissions rather than ambient concentrations, e.g., for a 
policy that requires the use of a specific control technology. Emission-based metrics also 
can identify specific emission sources that impose the greatest burden on the population 
given that contributions from specific sources to local air quality are known. The degree to 
which a specific source impacts the health of a population depends on a number of factors, 
including the proximity of the source to the population and local meteorological patterns. In 
order to use emissions-based metrics effectively, emissions inventory data need to be 
combined with dispersion modeling, population data, HIFs and the other data described 
previously (Fann et al., 2009). The case study assumed a 2 µg/m3 PM2.5 reduction using 
equal emissions reductions across multiple sectors, did not account for the distribution of 
sources in the population, and calculated aggregate benefits per ton. The highest benefit per 
ton of emissions reduced likely will occur for sources or sectors in populated areas that 
release pollutants near ground level, e.g., on- and off-road diesel engines in densely 
populated cities. Such analyses can be data intensive and potentially complex, thus data gaps 
and model uncertainties should be recognized and communicated to key decision makers 
and stakeholders. In cases, national average values for benefits per ton are available (e.g., 
US EPA, 2013b). However, each HIA scenario and each city may uniquely influence effects 
of location-specific characteristics (e.g., location, type, meteorological trends).
3.3.5 Uncertainty in health impact metrics—A simplified uncertainty analysis 
demonstrates the variability of HIA results due to CR estimates, identified as the single most 
important source of uncertainty for urban-scale HIAs (Chart-asa and Gibson, 2015). The 
most uncertain impacts are the low-severity outcomes, as shown by the wide confidence 
intervals (CIs) for the number of avoided impacts (Table 1). The CIs are symmetrical for 
mortality, respiratory and cardiovascular hospitalizations, emergency department visits, 
MRAD and WLD since the underlying CR estimates use log-linear models, while 
asymmetrical CIs result for non-fatal heart attacks and asthma exacerbations since these 
outcomes are based on logistic regression models. For the latter, the large upper "tail" of the 
distribution can greatly increase impacts, e.g., the MC analyses for non-fatal heart attacks 
and asthma exacerbations give means that are 6 and 11% higher, respectively, than the 
deterministic estimates that use the mean CR estimate (Table 1). Large CIs can cause 
additional issues, e.g., the 16% of the MC simulations for asthma exacerbations gave 
disbenefits (negative avoided impacts) (using the HIF estimate in Supplemental Table S3 
and a CR function drawn from a single study, Mar et al., 2004). Such implausible outcomes 
highlight the need to use CR estimates from well-powered studies that have small standard 
errors, to pool CR estimates among multiple studies, or to truncate negative avoided 
impacts.
Uncertainty estimates due to parameter uncertainty have been estimated using MC analyses, 
Bayesian methods, and sensitivity analyses, and a few HIAs have considered uncertainties in 
model structures (e.g., Baccini et al., 2015; Chanel et al., 2014; Chang et al., 2014; Chart-asa 
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and Gibson, 2015; Woodcock et al., 2014; Xia et al., 2015; reviewed in Mesa-Frias et al., 
2013). For the number of avoided cases, uncertainty arises from CR estimate, baseline 
health outcome rates, and changes in exposure concentrations. These uncertainties are 
propagated to and potentially increase for other metrics, e.g., as mentioned, additional 
uncertainties in DALYs include the duration of outcomes and the subjective assignment of 
disability weights. Similarly, monetized metrics must contend with the subjectivity and 
variability of valuations. Ideally, uncertainty analyses would consider all sources of 
variability, including dependencies among inputs. If the total uncertainties among competing 
mitigation strategies are very large, then quantitative HIAs may not inform the remedy 
selection, and decisions may rest on economic or other criteria. However, estimates of both 
health impacts and uncertainties can motivate the need for mitigation, especially if decision 
makers are risk averse (IOM, 2013). For example, an MC analysis examining health impacts 
due to vehicle emissions in Chapel Hill, North Carolina (examining uncertainty in CR 
estimates, PM2.5 emissions, exposure concentrations and demographics) gave a substantially 
higher number of cases compared to deterministic results (Chart-asa and Gibson, 2015). 
Such uncertainties should be calculated and reported to decision makers.
Quantitative uncertainty analyses themselves have shortfalls. There are substantial data gaps 
regarding the variability and uncertainty of data, as well as the interactions among variables. 
Many analyses use a simplified bounding approach that does not indicate the likelihood or 
confidence intervals of possible outcomes. As mentioned, weight-of-evidence limitations 
may preclude consideration of potentially important outcomes. For these reasons, 
characterizing the limitations of the uncertainty analysis itself is important.
3.3.6 Co-benefits of air pollution management—Although excluded in the case 
study, HIA metrics can incorporate co-benefits of pollution control policies. For example, 
incentivizing active transportation to replace short car trips reduces emissions and can 
increase physical activity with significant health benefits (Maizlish et al., 2013). Strategies 
that promote active and public transportation also decrease the frequency of traffic-related 
car crashes (Rojas-Rueda et al., 2013; Xia et al., 2015). Increasing tree cover in cities 
removes pollutants from urban air sheds (Nowak et al., 2013) and can be advantageous for 
surface cooling and storm water management (Loughner et al., 2012; Wang et al., 2008).
Climate change mitigation and adaptation are major co-benefits of air pollution 
management. The transportation sector is responsible for 27% of total greenhouse gas 
(GHG) emissions in the US (US EPA, 2015c) and 23% of CO2 emissions globally (IEA, 
2014). Transportation policies aimed at reducing primary pollutant emissions, particularly 
those that reduce travel demand or fuel consumption, lead to reductions in GHG emissions 
(McCollum and Yang, 2009). Comparisons between policy options should consider the 
health impacts of reduced primary pollutant emissions as well as the environmental and 
health benefits of reduced GHG emissions.
Co-benefits can be indirect, secondary in nature and long term, and thus difficult to assess. 
Still, using common metrics to link these outcomes to public health makes the health metrics 
more comprehensive and compelling. Again, appropriate outreach and education may be 
required to inform decision makers.
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3.3.7. Challenges of the use of quantitative HIA methods—A number of 
challenges may be encountered when applying the methods in this paper to other regions. 
First, urban-scale HIAs are best conducted using local baseline health data that reflect the 
health status of the population (Hubbell et al., 2009). Sub-national health data may not be 
available where public health resources are limited, e.g., developing countries, especially for 
morbidity outcomes (Boerma and Stansfield, 2007). Second, most epidemiological studies 
have been conducted in the USA and Europe where concentrations tend to be lower than 
other parts of the world, and CR estimates derived from these studies used in other 
populations have limitations, e.g., while the GBD risk estimates combine several exposure 
sources, estimates include only mortality outcomes and respiratory infections in young 
children (Burnett et al., 2014). Third, suitable (e.g., long-term) air quality data for exposure 
assessment may not be available in many regions. While concentrations can be estimated, 
e.g., satellite data and global chemical transport models have been used to derive 
concentrations at coarse spatial resolution (10 km × 10 km, van Donkelaar et al., 2010), such 
methods also have uncertainties and may not capture urban-scale patterns necessary for 
local-scale HIAs. Fourth, regions differ with respect to pollutant sources, e.g., vehicle 
emissions may dominate exposures in the developed countries, while cooking and home 
heating emissions from biomass combustion may dominate exposures in developing 
countries. Such differences will shape the nature of control strategies. Due to these and 
possibly other reasons, site-specific, comprehensive and quantitative HIAs may not be 
feasible in some regions. Still, approximations using the approach with surrogate or 
estimated data may be valuable, and can serve to highlight data gaps.
3.4 Recommendations
Several recommendations follow from our analysis of the literature and the case study. First, 
if requisite data are available, HIAs should use quantitative metrics to assess health impacts 
and provide meaningful evidence regarding health benefits to decision makers formulating 
air quality management plans (Fann et al., 2011). Quantitative analyses permit explicit 
comparisons between options, better characterization of the magnitude of impacts for 
specific outcomes, estimates of the total number of people affected, and a framing of health 
outcomes in the same manner as other policy considerations. Quantitative metrics also 
enable decision makers to more readily incorporate HIA results into the policy process 
(Davenport et al., 2006). Because they describe concentration-dependent impacts, such 
metrics allow estimates of benefits for air quality improvements that go beyond standard 
attainment. The case study example was limited to PM2.5 reductions, but multi-pollutant 
frameworks should be used (Dominici et al., 2010; Johns et al., 2012; Oakes et al., 2014).
Second, since no single metric fully meets the evaluative criteria, the use of several 
complementary indicators is recommended. The number of cases avoided is simple and easy 
to interpret, but does not account for the severity of the outcome. To be comprehensive, 
urban-scale HIAs should report the number of avoided cases for multiple relevant health 
outcomes, and cases should be disaggregated into subgroups to allow consideration of 
equity, location, race/ethnicity, age, and other relevant factors. Consideration of multiple 
health outcomes in quantitative HIAs yields estimates of the total number of people affected, 
an important indicator itself. However, such estimates may undercount the total number of 
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people affected since not all outcomes are captured. In addition, estimates of morbidity 
outcomes can have considerable uncertainty, and possible outcomes with limited evidence 
are excluded. Despite these limitations, inclusion of morbidity outcomes is important for 
evaluating strategies that may not lead to substantial numbers of avoided deaths, and for 
minimizing biases that would tend to underestimate the public health impacts. Estimates of 
morbidity outcomes and the number of people affected should be recognized as a "low end" 
estimate that complements all-cause mortality estimates, and that provides additional 
information useful for comparing among management options. DALYs incorporate the 
severity, duration and timing of outcomes, but are complex and require additional data 
inputs (including uncertain disability weights); moreover, decision makers may not readily 
understand this metric. Still, DALYs find widespread use in studies of population health, 
and can aggregate health impacts of policies and programs allowing comparisons across 
studies. Monetized impacts share many of the same uncertainties as DALYs, and similarly, 
are driven by mortality, however, these metrics are familiar to decision makers and can be 
used in other policy evaluations (e.g., cost-benefit analysis). No single summary measure 
fully captures societal impacts associated with morbidity. Still, HIAs should utilize a 
composite indicator like DALYs or monetized values that allow ranking of options.
Third, metrics should be tailored to the local context. Some metrics may be particularly 
useful and favored in certain applications. For example, emissions-based metrics can 
facilitate comparisons between sectors and between options within a sector, and maybe 
particularly useful if policy options involve control technologies or if monetized benefits per 
ton vary considerably by sector and source. Urban-scale HIAs are not limited to an 
emissions context, and can also be used to inform decision makers about the benefits of 
alternative exposure reduction strategies, e.g., use of vegetative buffers along highways, 
rerouting trucks to avoid residential neighborhoods, or use of indoor air filtration. Evidence 
from quantitative HIAs can encourage decision makers to implement such interventions, 
especially when the number of people affected is high and the intervention is viewed as cost-
effective.
Fourth, community values should be considered in selecting metrics that are appropriate for 
urban scale HIAs. DALYs and monetized impacts place a high value on mortality. However, 
morbidity outcomes are far more common. DALYs or dollars might poorly capture local 
attitudes regarding less severe outcomes, e.g., asthma exacerbations. Engagement with 
stakeholders at early stages of the HIA would best serve to prioritize outcomes and metrics 
(Dannenberg et al., 2006).
Fifth, HIAs are strengthened by drawing on local information, including emission and 
dispersion data, to understand source-receptor relationships, including spatial variability, 
demographic and vulnerability information, and epidemiological evidence for concentration-
response functions.
Sixth, environmental and health co-benefits of air quality management strategies, including 
climate change mitigation, should be identified. When requisite data are available, these co-
benefits should be quantified using the same metrics selected for air pollution health 
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impacts, thus increasing the comprehensiveness of the overall assessment of control 
strategies.
Lastly, quantitative HIAs may underestimate the total impact of a policy or program because 
certain environmental or health impacts cannot be reliably quantified. Qualitative methods 
can augment the quantitative analyses and identify potential health and environmental 
outcomes that do not have reliable CR estimates, e.g., cancer and adverse birth outcomes.
4. Conclusions
This study reviewed quantitative metrics in recent HIAs addressing air pollutant exposure, 
and developed evaluative criteria for selecting and using metrics. The metrics were 
illustrated in a case study for the Detroit, Michigan area. Quantitative metrics describing the 
direction, magnitude and severity of expected health impacts can help inform decision 
makers and elevate health concerns to the level of other political and economic drivers into 
evaluations of projects, programs and policies. Different metrics prioritize different health 
outcomes. For examples, the number of avoided cases emphasizes common but lower 
severity impacts (e.g., minor restricted activity days and asthma exacerbations), while 
monetized impacts and DALYs emphasize the relatively small number of premature 
mortalities.
A number of recommendations were developed for selecting metric appropriate for air 
quality applications. Metrics should be comprehensive, identify the number of people 
affected for each morbidity and mortality outcome, and clearly communicate both direct and 
indirect impacts. Further, metrics should use local data (e.g., baseline rates from the study 
population), incorporate outcomes of high public health importance, and represent the 
spatial and temporal dimensions of impacts. Uncertainties and limitations should be 
characterized quantitatively and qualitatively, and reported to decision makers. While 
appropriate metrics depend on the application, most HIAs would benefit from several 
metrics that capture impacts to specific population groups as well as overall health impacts.
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COI Cost of illness
COPD Chronic obstructive pulmonary disease
CR Concentration-response
DALYs Disability-adjusted life years
DW Disability weight
GBD Global burden of disease
GHG Greenhouse gas
HIA Health impact assessment
HIF Health impact function
IHD Ischemic heart disease
LC Lung, trachea and bronchus cancer
LCA Life cycle analysis
LE Life expectancy
MC Monte Carlo
MRAD Minor restricted activity days
NOx Oxides of nitrogen
O3 Ozone
PAF Population attributable fraction
PM2.5 Particulate matter less than 2.5 µm in diameter
QALY Quality adjusted life year
RIA Regulatory impact analysis
RR Relative risk
US EPA United States Environmental Protection Agency
VSL Value of a statistical life
VSLY Value of a statistical life year
WHO World Health Organization
WTP Willingness to pay
YLD Years living with disability
YLL Years of life lost
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HIAs have used many metrics, including avoided cases, DALYs and monetized impacts.
There is a need to identify appropriate metrics for use in urban-scale air pollution HIA.
Metrics should be comprehensive, spatially and temporally resolved, and account for 
vulnerability.
Metrics should evaluate and clearly present uncertainty.
The use of multiple metrics is suggested to fully characterize the impacts of a proposed 
policy.
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Number of avoided premature deaths and years of life lost (YLL) per year by age group in 
Wayne County for a reduction in PM2.5 concentration from 10 to 8 µg/m3.
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Table 1
Number of premature deaths and morbidities avoided per year in Wayne County due to a reduction in PM2.5 










All-cause premature mortality (>29 years, HIF) 190 (130–260) 1.16 10.48
All-cause premature mortality (>29 years, PAF) 190 (120–240) 1.13 10.22
Cause-specific mortality (>24 years, PAF method)2 230 3.55 12.61
Infant mortality (<1 year) 2 (0–3) 0.77 0.09
Minor restricted activity days (18–64 years) 37,000 (15,000–58,000) 0.44 2,040
Asthma exacerbations (6–18 years)3 28,000 (–34,000–76,000) 2.49 12,639
Work loss days (18–64 years) 21,000 (17,000–24,000) 0.92 1,148
Asthma emergency department visit (> 1 year)3 190 (49–323) 1.11 86.42
Non-fatal MI (≥ 18 years) 160 (29–260) 4.93 8.92
CV hospitalization (≥ 20years) 84 (56–110) 0.30 4.71
Pneumonia hospitalization (>64 years) 26 (4–47) 0.79 1.45
COPD hospitalization (≥20 years) 25 (15–36) 0.40 1.42
Asthma hospitalization (<65 years) 19 (7–30) 0.66 1.05
1
Number of avoided cases is rounded to two significant digits; 95% confidence interval in parentheses.
2
Sum of IHD, stroke, LC and COPD deaths estimated using the PAF method.
3
Among persons with asthma.
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Table 2
Rates of premature mortality, years of life lost and monetized impacts attributable to a reduction in PM2.5 










National 8.6 124.0 83,000
Wayne County (including Detroit) 10.5 163.6 101,000
Detroit 11.0 194.6 105,000
1
Monetized benefits are in 2010$ projected to a 2020 income level and rounded to the nearest whole number with two significant digits
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Table 3
DALYs and monetized impacts avoided per year for deaths, unscheduled hospitalizations and morbidity 


















Percent attributable to mortality 98.5 % 94.8%
1
DALYs are YLL for mortality outcomes and YLD for morbidity outcomes.
2
95% confidence interval in parentheses.
2
Monetized impacts are calculated using 2010$ projected to a 2020 income level and rounded to the nearest whole number with two significant 
figures.
3
Premature mortality is the sum of premature mortality among adults (>29 years, HIF method) and infant mortality (<1 year).
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Table 4








All-cause premature mortality (>29 years, HIF method) 0.067 643,845
Infant mortality (<1 year) 0.001 5,364
Minor restricted activity days (18–64 years) 13.058 888
Asthma exacerbations (6–18 years)2 9.844 571
Work loss days (18–64 years) 7.346 1,102
Asthma emergency department visit (> 1 year)2 0.067 29
Non-fatal MI (≥ 18 years) 0.057 8,173
CV hospitalization (≥ 20years) 0.030 1,247
Pneumonia hospitalization (>64 years) 0.009 334
COPD hospitalization (≥20 years) 0.009 264
Asthma hospitalization (<65 years) 0.007 107
Total monetized benefits 661,442
1
Monetized benefits are in 2010$ projected to a 2020 income level
2
Among persons with asthma
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Table 5
Criteria used to evaluate potential metrics or urban-scale health impact assessments.
Criterion Description and Implications References
Interpretability Readily understood by lay audiences without need for complex
technical explanations
AbouZahr et al., 2007;
Murray, 2007;
Comparability Can be compared between different populations, control
scenarios or policy alternatives
Sanderson et al., 2006
Walker et al., 2007
Comprehensiveness Measures the total impact on population health by including all
relevant outcomes relevant to the pollutant of interest
Considers timing and severity of the outcomes
Includes multiple exposure pathways or health determinants
(e.g., a public transit policy may reduce air pollution exposures
and promote physical activity)
Bell et al., 2011;
Rabl, 2003;
Wong et al., 2003
Representativeness Data inputs reflect the baseline health status and demographics
of the study population
Bell et al., 2011;
Hubbell et al., 2009
Spatial Resolution Air pollution concentration estimates and baseline health data
reflect the heterogeneity in a population’s demographics, health
status and exposures
The boundaries of the HIA are appropriate for the proposed
project or policy (i.e., city-wide policies vs. localized projects or
programs)
Batterman et al., 2014;
Kheirbek et al., 2013;
Thompson et al., 2014
Temporal Resolution Impacts of acute and chronic exposures assessed
Accounts for anticipated changes in population (e.g., age
structure, baseline rates) over time
Considers lag between the timing of exposure and outcome
occurrence
Bell et al., 2011;




Considers changes in multiple pollutants and pollutant
interactions (e.g., a policy to reduce PM may also influence NOx
or O3 concentrations which have additional impacts)
Burnett et al., 2005;
Dominici et al., 2010
Equity Disaggregates population subgroups by vulnerability or
susceptibility (i.e., race/ethnicity, age, geographic location)
Jerrett et al., 2004;
O’Neill et al., 2008
Consideration of
uncertainty
Identifies and evaluates uncertainty
Uncertainties are communicated effectively
Walker et al., 2007
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Table 6













Demonstrates the magnitude of an impact
on a population based on the number
people potentially affected
Population specific input data lead to
estimates that reflect underlying health
status and susceptibility to adverse
outcomes
Stratification based on vulnerability or
susceptibility may lead to equity
considerations
Comprehensiveness is dependent on the
identification and inclusion of all relevant
outcomes
Dependent on selection of CR and on the
baseline rates for outcomes
Provides no information on the duration
or permanence of the impacts
Not all health impacts are independent;
can lead to biased estimates if this
dependence is not accounted for
Cannot be compared directly across






Explains what fraction of the population
burden is attributable to air pollution
Indicates which option may be more
beneficial in reducing the incidence of a
specific adverse outcome
Interpretation can be limited if estimates







Makes metrics comparable between
populations of differing size
Rates can be harder to interpret for those
unfamiliar with their use (Walker et al., 2007)
2 DALYs Measures mortality and morbidity in one
metric using time as a common unit
Accounts for the severity and permanence
of an outcome (e.g., duration and disability
weight)
Age-weighting and assignment of
disability weights can be uncertain or
controversial
Diminished importance of morbidity
outcomes due to weighting factors
3 Monetized impacts Often used in regulatory analyses and
HIAs; can facilitate comparisons with
other types of impacts (e.g., economic)
Frames health outcomes in the same
manner as non-health considerations
Facilitate cost-effectiveness or cost-benefit
analyses
US EPA methods for monetized
premature mortality does not consider the
number of years of life lost, only the total
number of premature deaths
May not accurately reflect the total




Appropriate when changes in ambient
concentrations are difficult to predict but
estimated changes in emissions are
available
Can identify emission sources for targeted
reductions (e.g., sector specific metrics)
Need to account for the location,
proximity to populations, and type of
emissions source
Impacts (benefits) per ton estimates can
be very uncertain depending on the data
inputs
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